Literature DB >> 22081106

Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.

Patrick Yachimski1, Mari Mino-Kenudson, Margaret E Sherwood, William P Puricelli, Norman S Nishioka, Gregory Y Lauwers.   

Abstract

Cyclooxygenase-2 expression is upregulated in Barrett's esophagus and esophageal adenocarcinoma. Photodynamic therapy using porfimer sodium can result in ablation of dysplasia and intramucosal carcinoma, eradication of Barrett's esophagus, and restitution of squamous epithelium. The aim of this study was to determine the effect of photodynamic therapy on cyclooxygenase-2 expression in esophageal epithelium. Paired pre- and post-photodynamic therapy biopsy samples from the same anatomical levels of 20 individuals who had undergone photodynamic therapy for Barrett's esophagus with high-grade dysplasia and/or intramucosal carcinoma were immunostained using a cyclooxygenase-2 monoclonal antibody. Cyclooxygenase-2 expression was graded in squamous epithelium, Barrett's esophagus, and neoplasia (if present) as follows: grade 0 (no staining), grade 1 (staining in 1-10% of cells), grade 2 (staining in 11-90% of cells), and grade 3 (staining in >90% of cells). Pre-photodynamic therapy median cyclooxygenase-2 expression was grade 2 (range 1-3) in neoplastic foci and grade 1 (range 1-3) in nondysplastic Barrett's esophagus (P=0.0009 for pairwise comparison). With the exception of a few cells staining in the basal epithelial layers, median cyclooxygenase-2 expression was graded as 0 (similar to controls) in both pre-photodynamic therapy squamous epithelium and post-photodynamic therapy neosquamous epithelium. This was significantly lower when compared to either neoplastic foci (P<0.0001) or nondysplastic Barrett's esophagus (P<0.0001) pre-photodynamic therapy. Notably, in four patients with post-photodynamic therapy recurrent neoplasia, cyclooxygenase-2 expression returned to elevated levels. Cyclooxygenase-2 expression is elevated in Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma prior to photodynamic therapy. Following successful photodynamic therapy, cyclooxygenase-2 expression in neosquamous epithelium returns to a low baseline level similar to that observed in native esophageal squamous epithelium. Post-photodynamic therapy neoplastic recurrence is associated with elevated cyclooxygenase-2 expression. Prospective studies should determine whether cyclooxygenase inhibitors have a role as adjuvant therapy to prevent recurrence of Barrett's esophagus following endoscopic therapy. © Springer-Verlag 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22081106     DOI: 10.1007/s00428-011-1167-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

1.  On the histogenesis of Barrett's oesophagus and its associated squamous islands: a three-dimensional study of their morphological relationship with native oesophageal gland ducts.

Authors:  Rebecca A Coad; Anthony C Woodman; Philip J Warner; Hugh Barr; Nicholas A Wright; Neil A Shepherd
Journal:  J Pathol       Date:  2005-08       Impact factor: 7.996

2.  Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.

Authors:  Elisabeth I Heath; Marcia Irene Canto; Steven Piantadosi; Elizabeth Montgomery; Wilfred M Weinstein; James G Herman; Andrew J Dannenberg; Vincent W Yang; Albert O Shar; Ernest Hawk; Arlene A Forastiere
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

Review 3.  Barrett's esophagus.

Authors:  Gary W Falk
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

4.  Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.

Authors:  Hidekazu Kuramochi; Daniel Vallböhmer; Kazumi Uchida; Sylke Schneider; Nahid Hamoui; Daisuke Shimizu; Parakrama T Chandrasoma; Tom R DeMeester; Kathleen D Danenberg; Peter V Danenberg; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

5.  Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.

Authors:  Mandeep S Dhalla; Gaurav K Shah; Kevin J Blinder; Edwin H Ryan; Robert A Mittra; Asheesh Tewari
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

6.  Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells.

Authors:  Nico Hendrickx; Cédric Volanti; Ugo Moens; Ole Morten Seternes; Peter de Witte; Jackie R Vandenheede; Jacques Piette; Patrizia Agostinis
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

7.  Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.

Authors:  M France; P A Drew; T Dodd; D I Watson
Journal:  Dis Esophagus       Date:  2004       Impact factor: 3.429

8.  Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.

Authors:  Daisuke Shimizu; Daniel Vallböhmer; Hidekazu Kuramochi; Kazumi Uchida; Sylke Schneider; Parakrama T Chandrasoma; Hiroshi Shimada; Tom R DeMeester; Kathleen D Danenberg; Jeffrey H Peters; Steven R DeMeester; Peter V Danenberg
Journal:  Int J Cancer       Date:  2006-08-15       Impact factor: 7.396

9.  Patient predictors of esophageal stricture development after photodynamic therapy.

Authors:  Patrick Yachimski; William P Puricelli; Norman S Nishioka
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02-06       Impact factor: 11.382

10.  Retinoic acid-induced glandular differentiation of the oesophagus.

Authors:  Chih-Long Chang; Pierre Lao-Sirieix; Vicki Save; Guillermo De La Cueva Mendez; Ron Laskey; Rebecca C Fitzgerald
Journal:  Gut       Date:  2006-12-21       Impact factor: 23.059

View more
  2 in total

1.  Biomarkers in exploring the frontiers of diagnosis, prognosis, and therapy of Barrett's esophagus.

Authors:  Patrick Yachimski; Richard M Peek
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

Review 2.  Barrett's oesophagus: an ideal model to study cancer genetics.

Authors:  Massimiliano di Pietro; Rebecca C Fitzgerald
Journal:  Hum Genet       Date:  2009-04-14       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.